Latest Capital Raises News

Wisr Limited reports robust half-year growth with a 23% increase in its loan book and a 14% rise in revenue, setting the stage for expected cash profitability in the second half of FY26.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Amplitude Energy has delivered a standout half-year performance with record gas production and a 246% jump in profit, while advancing key projects and strengthening its balance sheet.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.

Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.

Big River Industries has posted a $1.4 million profit for the half-year ending December 2025, reversing a substantial loss from the previous year, while completing a strategic acquisition in Perth.

Rox Resources is advancing rapidly toward ore production at its Youanmi Gold Project, with underground mining progress, drilling programs underway, and critical plant construction contracts secured.

AuMEGA Metals has confirmed a $30 million oversubscribed financing led by Condire Investors to fund expanded drilling and exploration in Newfoundland. The capital raise is structured in two tranches, with the first closing expected in early March and the second pending shareholder approval.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Bapcor Limited has postponed its half-year financial results release to no later than 27 February 2026 and is seeking an extension of its trading suspension, hinting at a potential capital raising.

Eminence Minerals Limited has issued 2.7 million unquoted CEO performance rights as part of a new executive appointment, utilising its 15% placement capacity without shareholder approval.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.